We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
ClinicalTrials.gov Menu

Study to Evaluate the Safety and Tolerability of PBI-4050 in Type 2 Diabetes Patients With Metabolic Syndrome

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02562573
Recruitment Status : Completed
First Posted : September 29, 2015
Last Update Posted : April 11, 2017
Information provided by (Responsible Party):
Liminal BioSciences Ltd.

Brief Summary:

This is a Phase 2, open-label, single-arm study of the safety and tolerability of PBI-4050 800 mg daily oral administration in type 2 diabetes patients with metabolic syndrome.

A total of 12 patients will initially be enrolled for study participation. A Data Safety Monitoring Board (DSMB) will continuously review data obtained from the 12 patients. When the 12 patients have completed at least one month of study treatment, the DSMB will meet and determine whether additional patients may be enrolled or the study should be stopped. If the safety is deemed acceptable to continue with the study, the study will enroll a maximum of 36 patients.

Condition or disease Intervention/treatment Phase
Type 2 Diabetes Metabolic Syndrome Drug: PBI4050 Phase 2

Detailed Description:

This Phase 2 study will be performed by 1 site in Canada. The total duration of study participation for each patient is at least 18 weeks and comprises 6 study visits.

Patients who choose to participate in the extension study will be in the study for a total of up to 32 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Tolerability of PBI-4050 in Type 2 Diabetes Patients With Metabolic Syndrome
Study Start Date : May 2015
Actual Primary Completion Date : November 2016
Actual Study Completion Date : November 2016

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: PBI4050
Four 200 mg capsules (total 800 mg) administered orally, once a day.
Drug: PBI4050

Primary Outcome Measures :
  1. Number of subjects with abnormal laboratory values and/or adverse events that are related to treatment [ Time Frame: 7 months ]

Secondary Outcome Measures :
  1. Change from baseline on waist circumference [ Time Frame: 6 months ]
  2. Change from baseline on biomarkers [ Time Frame: 6 months ]
    % reduction and/or increase of biomarkers

  3. Change from baseline on antidiabetic treatment [ Time Frame: 6 months ]
    Treatment discontinued, dosing change, and/or new medication added

  4. Change from baseline on triglycerides [ Time Frame: 6 months ]
  5. Change from baseline on BP [ Time Frame: 6 months ]
  6. Change from baseline on HDL-C [ Time Frame: 6 Months ]
  7. Change from baseline on fasting plasma glucose [ Time Frame: 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patient is 18 years of age or older.
  2. Patient has signed written informed consent.
  3. Patient has a clinical diagnosis of type 2 diabetes mellitus with a hemoglobin A1c (HbA1c) level between 7% and 10%.
  4. Patient has been receiving stable antidiabetic therapy (oral agents with or without basal insulin given once daily in the evening) for a minimum of 3 months before the screening visit.
  5. Patient is able and willing to self-monitor blood glucose level at home.
  6. Patient has a body mass index (BMI) of at least 27 kg/m2.
  7. Patient has metabolic syndrome, having at least 3 of the 5 metabolic syndrome risk factors.

Exclusion Criteria:

  1. Patient requires intensive insulin therapy (defined as more than basal insulin given once daily in the evening) in addition to oral hypoglycemic agents for blood glucose control.
  2. Patient has recent or on-going infection requiring systemic treatment with an anti-infective agent within 30 days before screening.
  3. Patient has had at least one episode of severe hypoglycemia in the past 12 months, defined as having a blood glucose level < 3.0 mmol/L and/or requiring third party assistance to treat hypoglycemic episode.
  4. Patient has evidence of significant cardiovascular disease, including myocardial infarction, unstable angina, coronary bypass surgery, percutaneous transluminal coronary angioplasty (PTCA), congestive heart failure (New York Heart Association Class III-IV), stroke, or severe ischemic disease within 3 months before screening.
  5. Patient has uncontrolled hypertension with BP > 150/95 mm Hg.
  6. Patient has a diagnosis of rheumatic or inflammatory disease, such as rheumatoid arthritis (RA), polymyalgia rheumatic (PMR), inflammatory bowel disease (IBD); or other autoimmune or inflammatory disease such as systemic lupus erythematosus (SLE) or psoriasis.
  7. Patient is concurrently taking and plans to routinely continue taking anti-inflammatory medications, such as nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, during the study.
  8. Patient is currently using weight loss medications.
  9. Patient has significantly elevated liver enzyme levels, defined as alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 2.5 × upper limit of normal (ULN) or total bilirubin above ULN.
  10. Patient has a history of chronic alcohol or other substance abuse.
  11. Woman who is pregnant, breast-feeding, or planning a pregnancy during the course of the study.
  12. Woman of childbearing potential who is unwilling to use adequate birth control throughout the duration of the study.
  13. Patient has any condition that, in the investigator's opinion, is likely to interfere with study conduct and compliance.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02562573

Layout table for location information
Canada, Alberta
Edmonton, Alberta, Canada
Sponsors and Collaborators
Liminal BioSciences Ltd.
Layout table for additonal information
Responsible Party: Liminal BioSciences Ltd.
ClinicalTrials.gov Identifier: NCT02562573    
Other Study ID Numbers: PBI4050-ATX-9-04
First Posted: September 29, 2015    Key Record Dates
Last Update Posted: April 11, 2017
Last Verified: October 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Metabolic Syndrome
Pathologic Processes
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Insulin Resistance